| 1. |
Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med, 2010, 363(12): 1128-1138.
|
| 2. |
张小贺. 阿奇霉素联合细菌溶解产物对慢阻肺合并支气管扩张疾病的临床效果. 唐山: 华北理工大学, 2023.
|
| 3. |
Lewis PO. Risk factor evaluation for methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa in community-acquired pneumonia. Ann Pharmacother, 2021, 55(1): 36-43.
|
| 4. |
中华医学会呼吸病学分会感染学组. 中国铜绿假单胞菌下呼吸道感染诊治专家共识(2022 年版). 中华结核和呼吸杂志, 2022, 45(8): 739-752.
|
| 5. |
Pisa D, Alonso R, Carrasco L. Parkinson’s disease: a comprehensive analysis of fungi and bacteria in brain tissue. Int J Biol Sci, 2020, 16(7): 1135-1152.
|
| 6. |
Maggiorelli C, Di Pierro I, Manta C, et al. Nocardia and lungs in COPD: beyond immuno-deficiencies. COPD, 2015, 12(3): 315-319.
|
| 7. |
刘艳红, 韦晓山, 苏远, 等. 盖尔森基兴诺卡菌致肺部感染病例 1 例. 临床医学进展, 2024, 14(5): 68-72.
|
| 8. |
李柔, 杨斌, 曾宪春, 等. 支气管扩张症合并铜绿假单胞菌感染: 2012-2022 年的文献计量学分析及可视化研究. 中国感染与化疗杂志, 2024, 24(1): 8-18.
|
| 9. |
Martínez-García MÁ, Faner R, Oscullo G, et al. Risk factors and relation with mortality of a new acquisition and persistence of Pseudomonas aeruginosa in COPD patients. COPD, 2021, 18(3): 333-340.
|
| 10. |
Qin SG, Xiao W, Zhou CM, et al. Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. Signal Transduct Target Ther, 2022, 7(1): 199.
|
| 11. |
Lederman ER, Crum NF. A case series and focused review of nocardiosis: clinical and microbiologic aspects. Medicine (Baltimore), 2004, 83(5): 300-313.
|
| 12. |
刘俊枫, 周伟, 高鹏, 等. 甘肃省 10 例诺卡菌病患者的临床特征. 中国感染控制杂志, 2022, 21(7): 661-667.
|
